期刊
JOURNAL OF EXPERIMENTAL MEDICINE
卷 215, 期 1, 页码 21-33出版社
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20171773
关键词
-
资金
- National Institutes of Health [R01HL039006, R01HL125865, P01HL129941, 14SFRN20420046, F31HL127986]
- National Institutes of Health National Heart, Lung, and Blood Institute K08 award [HL121671]
- Gilead Cardiovascular Scholars Grant
- National Institutes of Health DP2 award [HL137166]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039006, P01HL129941, DP2HL137166, F31HL127986, K08HL121671, R35HL140016, R01HL125865] Funding Source: NIH RePORTER
Although systemic hypertension affects a large proportion of the population, its etiology remains poorly defined. Emerging evidence supports the concept that immune cells become activated and enter target organs, including the vasculature and the kidney, in this disease. Mediators released by these cells, including reactive oxygen species, metalloproteinases, cytokines, and antibodies promote dysfunction of the target organs and cause damage. In vessels, these factors enhance constriction, remodeling, and rarefaction. In the kidney, these mediators increase expression and activation of sodium transporters, and cause interstitial fibrosis and glomerular injury. Factors common to hypertension, including oxidative stress, increased interstitial sodium, cytokine production, and inflammasome activation promote immune activation in hypertension. Recent data suggest that isolevuglandin-modified self-proteins in antigen-presenting cells are immunogenic, promoting cytokine production by the cells in which they are formed and T cell activation. Efforts to prevent and reverse immune activation may prove beneficial in preventing the long-term sequelae of hypertension and its related cardiovascular diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据